scispace - formally typeset
Journal ArticleDOI

Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities.

Robert S. Rosenson
- 01 Jul 2005 - 
- Vol. 20, Iss: 4, pp 313-317
TLDR
As high levels of low- density lipoprotein particles are a robust predictor of cardiovascular events, strategies targeted at raising low levels of high-densitylipoprotein cholesterol must account for low-density lipop protein particle interactions.
Abstract
Purpose of review Discuss the contribution of low-density lipoprotein subclass abnormalities to cardiovascular risk among individuals with low high-density lipoprotein cholesterol levels. Recent findings Low high-density lipoprotein cholesterol levels are commonly encountered among patients with early onset cardiovascular disease. Most often, a low high-density lipoprotein cholesterol level is not an isolated abnormality, but it is usually associated with a number of other lipoprotein abnormalities. Data from the Framingham Offspring Study demonstrate that among subjects with high-density lipoprotein cholesterol, 1.0 mmol/L (39 mg/dL), low-density lipoprotein particle numbers were considerably higher than indicated by the level of low-density lipoprotein cholesterol because these subjects had excess numbers of small cholesterol-depleted low-density lipoprotein particles. Elevated numbers of low-density lipoprotein particles identify individuals at highest risk for atherosclerotic vascular disease and cardiovascular events. Summary As high levels of low-density lipoprotein particles are a robust predictor of cardiovascular events, strategies targeted at raising low levels of high-density lipoprotein cholesterol must account for low-density lipoprotein particle interactions.

read more

Citations
More filters
Journal ArticleDOI

Modulation of fatty acid transport and metabolism by maternal obesity in the human full-term placenta.

TL;DR: Overall this study demonstrated that maternal obesity impacts placental FA uptake without affecting fetal growth, however, these changes could modify the fetus metabolism and its predisposition to develop diseases later in life.
Journal ArticleDOI

Systematic Review, Meta-Analysis and Regression of Randomised Controlled Trials Reporting an Association Between an Intake of Circa 25 G Soya Protein Per Day and Blood Cholesterol

TL;DR: The inclusion of modest amounts soya protein into the diet of adults with normal or mild hypercholesterolaemia resulted in small, highly significant reductions in total and LDL cholesterol, equivalent to ca.
Journal ArticleDOI

Discovery of a New Role of Human Resistin in Hepatocyte Low-Density Lipoprotein Receptor Suppression Mediated in Part by Proprotein Convertase Subtilisin/Kexin Type 9

TL;DR: Results reveal for the first time that resistin is a highly attractive therapeutic target in ameliorating elevated serum low-density lipoprotein and, thereby, atherosclerotic cardiovascular diseases in obese humans.
Journal ArticleDOI

Cardiovascular risks in spondyloarthritides.

TL;DR: Novel findings regarding cardiac and vascular pathologies and potential overlapping mechanisms will be discussed, and the beneficial effects of statin treatment on circulating inflammatory mediators and atherogenic lipid profiles may reveal new therapeutic options for patients with spondyloarthritides.
References
More filters
Journal ArticleDOI

Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey

TL;DR: These results from a representative sample of US adults show that the metabolic syndrome is highly prevalent and the large numbers of US residents with the metabolic Syndrome may have important implications for the health care sector.
Journal ArticleDOI

Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS

TL;DR: Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL- C levels and supports the inclusion of HDL-C in risk-factor assessment and the need for reassessment of the National Cholesterol Program guidelines.
Journal ArticleDOI

Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol

TL;DR: Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level, suggesting that the rate of coronary events is reduced by raising HDL cholesterol levels and lowering levels of triglycerides without lowering LDL cholesterol levels.
Related Papers (5)